Search clinical trials for: BMS-663513

Total 3138 results

Bristol-Myers Squibb

Terminated

Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities

Primary Familial Dilated Cardiomyopathy

United States, Germany, Spain, United Kingdom
Boehringer Ingelheim

Completed

Bioequivalence of IVAX Warfarin Tablets and Coumadin Brand Warfarin Tablets in Healthy Volunteers

Healthy
Bristol-Myers Squibb

Completed

Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction (PK)

Chronic Hepatitis C Virus Infection | Chronic Hepatitis B Virus Infection

United States
Bristol-Myers Squibb

Completed

A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma (TIME-2)

Multiple Myeloma

United States
Bristol-Myers Squibb

Completed

Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

Breast Cancer | Solid Tumors

United States
Bristol-Myers Squibb

Completed

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

Hepatitis C

United States, Australia, Canada, France, Puerto Rico
Bristol-Myers Squibb

Completed

Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance

Type 2 Diabetes

Russian Federation
Bristol-Myers Squibb

Terminated

Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment (BRISK-APS)

Carcinoma, Hepatocellular

China, Korea, Republic of, Taiwan, Singapore
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

BMS-188797 and Carboplatin in Treating Patients With Advanced Nonhematologic Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

Hepatocellular Carcinoma | Hepatoma | Liver Cell Carcinoma | Liver Cancer, Adult | Liver Cell Carcinoma, Adult

Chile, Brazil, Argentina, China, Czechia, France, Hong Kong, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Romania, Singapore, Spain, Taiwan, Turkey
Robert R. McWilliams, MD
Bristol-Myers Squibb; Hoosier Cancer Research Network

Active, not recruiting

Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

Mucosal Melanoma

United States
Pfizer
Bristol-Myers Squibb

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Multiple Myeloma

United States, Canada
Bristol-Myers Squibb

Recruiting

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF)

Heart Failure

United States, Spain, Canada, Italy, Poland
Celgene

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Primary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis

France, Belgium, Spain, Australia, Canada, United States, Korea, Republic of, Romania, Japan, Israel, Italy, Austria, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Colombia, Argentina, Chile and more
Bristol-Myers Squibb

Active, not recruiting

A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy (HORIZON-HCM)

Cardiomyopathy, Hypertrophic Obstructive

Japan
Bristol-Myers Squibb

Completed

A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Follicular Lymphoma | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Diffuse Large B-Cell Leukemia

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

Neoplasms by Site

United States, Mexico, Italy, Argentina, Brazil, Chile, France, Netherlands, New Zealand, Poland, Spain, United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Completed

Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy

Recurrent Uterine Corpus Sarcoma | Uterine Corpus Leiomyosarcoma

United States
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Bladder Cancer | Bladder Tumor | Muscle-Invasive Bladder Cancer

Russian Federation, China, Germany, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Greece, Israel, Mexico, Netherlands, Poland, Spain, United Kingdom
Bristol-Myers Squibb

Terminated

Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis

Healthy Volunteers | Ulcerative Colitis

Australia, Georgia, Moldova, Republic of
Bristol-Myers Squibb

Completed

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

CANCER,NOS

France, Canada, United States, Switzerland, Spain, Italy
Bristol-Myers Squibb

Recruiting

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Melanoma | Carcinoma, Renal Cell | Cervical Cancer | Pancreatic Adenocarcinoma | Ovarian Neoplasms | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Urothelial Carcinoma | Microsatellite Stable Colorectal Cancer | Non-Small-Cell Lung Cancer | Gastric/Gastroesophageal Junction...

United States, Australia, Italy, Germany, Spain, Canada, Israel, Japan
Bristol-Myers Squibb

Completed

A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Australia, Italy, Canada, United States, Germany, Spain, France
Bristol-Myers Squibb

Completed

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (D-LITE)

Hepatitis C

United States
Bristol-Myers Squibb

Completed

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

Hepatitis C

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

Advanced Cancer

China
Boehringer Ingelheim

Completed

Bioequivalence Study of Two Strengths of Two Different Metformin Tablets Administered to Healthy Male and Female Subjects

Healthy
Bristol-Myers Squibb

Withdrawn

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Lung Cancer

Italy, Korea, Republic of, Turkey, Canada, Spain, Australia, Mexico, Taiwan, France, Germany, Switzerland, Greece, Japan, Austria, United States, Brazil, Czechia
Riphah International University

Completed

Neuromuscular Electrical Stimulation With and Without Constraint Induced Movement Therapy in Erb's Palsy

Erb's Palsy

Pakistan
University of Michigan
National Institute on Drug Abuse (NIDA)

Completed

Project Chill: Tailored Youth Drug Intervention In Primary Care

Marijuana Use
Bristol-Myers Squibb

Recruiting

A Study to Determine the Efficacy and Safety of Luspatercept in Adult and Adolescent Participants With Alpha (α)-Thalassemia

Anemia

Thailand, China, Canada, Turkey, Greece, Taiwan, Italy, Hong Kong
University Medical Center Groningen

Completed

PD-L1 PET Imaging in Melanoma Patients

Melanoma

Netherlands
Chimerix

Terminated

A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304

Adenovirus

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer

Colorectal Cancer

United States, Canada
Bristol-Myers Squibb

Terminated

Safety Study of BMS-844421 for Treatment of Hypercholesterolemia

Atherosclerosis | Hypercholesterolemia

Germany
Bristol-Myers Squibb

Terminated

Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)

Non-small Cell Lung Cancer

Spain, Belgium, France, Italy, Netherlands, Canada, United Kingdom, United States
Hospital for Special Surgery, New York

Completed

Intra-articular Autologous Bone Marrow Aspirate Injection for Knee Osteoarthritis

Osteoarthritis, Knee

United States
Bristol-Myers Squibb

Completed

Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese Participants

Healthy Volunteers

United States
Xuanwu Hospital, Beijing

Completed

Bare -Metal Stents and Drug -Eluting Stents in the Treatment of Patients With Vertebral Artery Ostium Stenosis

Ischemic Stroke

China
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Recruiting

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM)

Cardiomyopathy, Hypertrophic

Japan, United States, Spain, Korea, Republic of, Israel, United Kingdom, Norway, Germany, Brazil, Belgium, Hungary, Austria, China, Netherlands, France, Poland, Canada, India, Italy, Portugal, Denmark, Australia, Czechia
LianBio LLC

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

Obstructive Hypertrophic Cardiomyopathy

China
Bristol-Myers Squibb

Completed

Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC (BRISK TA)

Hepatocellular Carcinoma

United States, Argentina, Australia, Canada, China, France, Hong Kong, Italy, Japan, Korea, Republic of, Taiwan, Thailand, Spain
National Cancer Institute (NCI)

Completed

Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Recurrent Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) and other conditions

United States
Radboud University Medical Center
Bristol-Myers Squibb

Active, not recruiting

Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer (INSPIRE)

Prostatic Neoplasms, Castration-Resistant

Netherlands

3

Subscribe